Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GECO: Rofecoxib + Cisplatin/Gemcitabine in Advanced NSCLC
NCT00385606Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rofecoxib, gemcitabine in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jan 2003; status: completed.
02
Drugs
rofecoxibgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00385606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385606.